Coherus BioSciences Stock Forecast NASDAQ:CHRS

Price Target and Analyst Ratings

Most Recent Rating

On August 06, 2021 "Maxim Group" gave "$22.00" rating for CHRS. The price target was set to $13.02+0.0%.

Last 30 Days

Historical Ratings

Date	Rating	Action	Authority	Current Price	Target Price
2021-08-06	$22.00	Initiated by	Maxim Group	$13.02	$13.02+0.0%
2021-07-23	$26.00 - $36.00	Target Raised by	HC Wainwright	$13.07	$12.68→3.4%
2021-05-24	Overweight	Target Lowered by	Barclays	$13.19	$28.00 → $24.00
2021-05-17	Overweight	Target Lowered by	Barclays	$14.14	$28.00 → $24.00
2021-05-13	Buy	Target Lowered by	HC Wainwright	$13.89	$29.00 → $26.00
2021-05-07	Buy	Initiated by	Maxim Group	$14.32	$22.00
2021-05-07	Buy	Target Lowered by	HC Wainwright	$14.32	$28.00 → $26.00
2021-03-03	Buy	Target Lowered by	HC Wainwright	$15.43	$33.00 → $29.00
2021-02-25	Buy	Reiterated by	HC Wainwright	$15.25	$33.00 → $29.00
2021-02-25	Buy	Target Lowered by	HC Wainwright	$15.25	$33.00 → $29.00
2021-02-25		Target Lowered by	Citigroup	$15.25	$30.00 → $27.00
2020-11-19	Buy	Target Lowered by	Mizuho	$17.92	$35.00 → $30.00
2020-11-06	Buy	Target Lowered by	HC Wainwright	$16.68	$33.00 → $32.00
2020-08-07	Buy	Initiated by	Maxim Group	$19.63	$27.00
2020-08-07	Buy	Target Raised by	HC Wainwright	$19.63	$30.00 → $33.00
2020-07-16	Neutral	Initiated by	BofA Securities	$18.30	$20.00
2020-07-16	Neutral	Initiated by	Bank of America	$18.30	$20.00
2020-05-08	Buy	Reiterated by	HC Wainwright	$17.30	$30.00
2020-04-17	Buy	Initiated by	SunTrust Banks	$15.53	$26.00

CHRS Stock Trend

The stock lies in the middle of a wide and strong rising trend in the short term and a further rise within the trend is signaled.

Given the current short-term trend, the stock is expected to rise 13.8% during the next 3 months and, with a 90% probability hold a price between $15.91 and $19.70 at the end of this 3-month period.

WARNING: Trend forecast is still in the development phase and should be used with caution. Some cases might produce unexpected results such as negative prices at the end of the trend.

Data

Date	Bottom	Mid	Top
2021-09-20	$14.01	$15.68	$17.34
2021-09-21	$14.05	$15.71	$17.38
2021-09-22	$14.08	$15.74	$17.41
2021-09-23	$14.11	$15.78	$17.44
2021-09-24	$14.15	$15.81	$17.48
2021-09-27	$14.18	$15.84	$17.51
2021-09-28	$14.21	$15.88	$17.54
2021-09-29	$14.25	$15.91	$17.58
2021-09-30	$14.28	$15.94	$17.61
2021-10-01	$14.31	$15.98	$17.64
2021-10-04	$14.35	$16.01	$17.68
2021-10-05	$14.38	$16.04	$17.71
2021-10-06	$14.41	$16.08	$17.74
2021-10-07	$14.45	$16.11	$17.78
2021-10-08	$14.48	$16.14	$17.81
2021-10-11	$14.51	$16.18	$17.84
2021-10-12	$14.55	$16.21	$17.88
2021-10-13	$14.58	$16.24	$17.91
2021-10-14	$14.61	$16.28	$17.94
2021-10-15	$14.65	$16.31	$17.98
2021-10-18	$14.68	$16.34	$18.01
2021-10-19	$14.71	$16.38	$18.04
2021-10-20	$14.75	$16.41	$18.08
2021-10-21	$14.78	$16.44	$18.11
2021-10-22	$14.81	$16.48	$18.14
2021-10-25	$14.85	$16.51	$18.17
2021-10-26	$14.88	$16.54	$18.21
2021-10-27	$14.91	$16.58	$18.24
2021-10-28	$14.95	$16.61	$18.27
2021-10-29	$14.98	$16.64	$18.31

About Coherus BioSciences

Coherus Biosciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The companys product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which has completed a Phase I study for the prevention of chemotherapy-induced neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in Phase III clinical trials for the treatment of rheumatoid ar... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!